glp-1 news today 2025 november in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity FDA bans compounded GLP-1 drugs

This growth presents both opportunities and challenges for the pharmaceutical sector, prompting the need for enhanced regulatory scrutiny

Just practical and relatable

Medical professionals need to watch for BP in patients using GLP-1RAs when they develop new blistering skin lesions

A return to the dermatologist for updated labs, repeat scalp examination, and possibly biopsy is appropriate at this stage

More recently, in March 2024, Wegovy was This approval followed promising results from novo Nordisks SELECT trial, which followed 17,604 adults with obesity or overweight and cardiovascular disease but no history of diabetes